<DOC>
	<DOCNO>NCT02837978</DOCNO>
	<brief_summary>This study design observe prospectively efficacy safety 6 month treatment Tacrolimus alone methotrexate ( MTX ) moderate severe Chinese RA patient show insufficiency response intolerance DMARDs</brief_summary>
	<brief_title>The Clinical Efficacy Safety Tacrolimus Refractory Rheumatoid Arthritis Patients 6 Months Treatment</brief_title>
	<detailed_description>This study enroll 100 case refractory rheumatoid arthritis ( RA ) patient Chinese，who moderate severe disease activity insufficiency response intolerance DMARDs . The participant plan treat Tacrolimus alone , along methotrexate ( MTX ) participant tolerant MTX . The efficacy safety 6 month Tacrolimus treatment RA patient evaluate DAS28 disease activity index .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Patients diagnose base 1987 ACR classification criterion rheumatoid arthritis 2 . Age ≥18 year ; 3 . Medium high disease activity ( DAS28≥3.2 ) ; 4 . Extraarticular manifestation ( pulmonary fibrosis , proteinuria , leukopenia peripheral neuropathy ) RA patient stable significant progress ; 5 . Patients treat biologic drug ; 6 . Patients history baseline medication methotrexate ( MTX ) DMARDs drug ( leflunomide , hydroxychloroquine , iguratimod , sulfasalazine , tripterygium Glycosides ) 3 month , could n't achieve clinical remission low disease activity ; could n't tolerate one DMARDs , DAS28≥3.2 ; 7 . Dose prednisone NSAIDs remain stable least one month . 1 . Patients acute chronic infection active bacterial , viral , fungal , tuberculosis infection active hepatitis B ; 2 . Platelet count ( PLT ) &lt; 80 x 10^9 / L , white blood cell ( WBC ) &lt; 3 x 10^9 / L ; 3 . Propionate acid aminotransferase ( ALT ) aspartate aminotransferase ( AST ) two time higher upper limit normal ; 4 . Renal insufficiency : serum Cr ≥ 176 umol / L ; 5 . Pregnant nursing woman ( breastfeed ) ； 6 . Patients history malignancy ( cure time le 5 year ) ; 7 . Patients severe poorly control hypertension , diabetes cardiac dysfunction ; 8 . Other comorbidities treat immune suppressant . In addition , patient experience severe adverse drug reactions、ineffective treatment rapid progression rheumatoid arthritis , quit research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Safety</keyword>
</DOC>